Breaking News

FDA Roundup: December 6, 2022 Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology Statement by Assistant Secretary for Mine Safety and Health Williamson recognizing America’s mine workers on National Miners Day Daily Press Briefing by the Office of the Spokesperson for the Secretary-General Wellesley Island Border Patrol Agents and the Jefferson County Sheriff’s Office Seized Approximately 150 Pounds of Marijuana Governor Cooper Announces Alamance Foods Will Expand and Create 135 Jobs FEMA Awards Almost $4.5 Million to Manchester-by-the-Sea to Fight Flooding Readout of Deputy Secretary of Defense Dr. Kathleen H. Hicks’ Meeting With U.K. Permanent Under Secretary of Defence David Williams

Issued: London UK

GlaxoSmithKline (GSK) confirmed today that the European Commission (EC) has granted an amendment of their marketing authorisation for their anti-clotting agent (antithrombotic) Arixtra® (fondaparinux) in the European Union for a new therapeutic indication. Fondaparinux 1.5 and 2.5 mg is now indicated for thetreatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis. It is the only anti-clotting agent to have this indication.

Fondaparinux 1.5 and 2.5 mg is currently approved for use in the EU for the prevention of venous thromboembolic events (VTE), 2.5 mg is additionally approved for the treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) and for the treatment of ST segment elevation myocardial infarction (STEMI) and 5mg, 7.5mg and 10mg are approved for initial treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE).

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

GlaxoSmithKline enquiries

   

UK Media enquiries:

Philip Thomson

(020) 8047 5502

 

Claire Brough

(020) 8047 5502

 

Stephen Rea

(020) 8047 5502

 

Alexandra Harrison

(020) 8047 5502

 

Jo Revill

(020) 8047 5502

 

 

 

European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564

 

Sally Ferguson

(020) 8047 5543

 

Gary Davies

(020) 8047 5503

Source link